Jean-Pierre Gerber
Portefeuillebeheerder-Aandelen bij Bellevue Asset Management AG
Profiel
Mr. Jean-Pierre Gerber is a Product Specialist at Bellevue Asset Management AG.
He formerly worked as Head of Fund Research and Equity Product Specialist for Julius Baer Asset Management, and as a Business Audit and Consulting Associate for Ernst & Young.
Mr. Gerber holds a Master's degree in Business Economics, following studies at the University of Berne and the University of Warwick, UK.
Actieve functies van Jean-Pierre Gerber
| Bedrijven | Functie | Begin |
|---|---|---|
Bellevue Asset Management AG
 Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Portefeuillebeheerder-Aandelen | 01-01-2009 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Bellevue Asset Management AG
Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Finance |
